UCDCC#303: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Rituxan (rituximab) - Roche

doxorubicin hydrochloride - Generic mfg.

vincristine - Generic mfg.

prednisone delayed-release tablet - Generic mfg.

etoposide IV - Generic mfg.

cyclophosphamide - Generic mfg.

Zynlonta (loncastuximab tesirine-lpyl) - Overland ADCT BioPharma

Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku

daunorubicin - Generic mfg.

UCDCC#303: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 28, 2026 - P2 | N=24 | Active, not recruiting | Sponsor: University of California, Davis | Recruiting ➔ Active, not recruiting
Enrollment closed • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BCL2 • BCL6 • CD4

http://clinicaltrials.gov/ct2/show/NCT05600686

Sep 28, 2026